Not sure what you are talking about when you mentioned "lose on their revenue".
When a company provides a letter of authorization to the BRH, this letter will include the committment of BGMP fee as well, and its associated BRH service fee. When a company opts for the MDSAP then obviously the BRH will lose on their revenue. Hence a BRH will never encourage company to take up MDSAP. Their ABIMED comes in handy to speeden up the process. Perhaps the BRH never know the parallel MDSAP process now exists as a pilot on a 3 year trial period
Unlike ANVISA BGMP fee, the FDA do not charge any fee, and there are no mediators between FDA and company.
Now comes the next catch. When a company takes up the MDSAP, they pay the AO. If the company waits for FDA, its free. But when FDA inspection is applicable to the company, and the company wants to expand the market, then MDSAP may help. They therefore land up paying the AO and eventually cover the FDA inspection also at a cost.
So how popular is this MDSAP after 16 months of pilot out of the 36 months which included the AO recognition period as well ... ??